Theravance Biopharma has appointed Gary Barrera as Head, Quality. Barrera joins Theravance from Boehringer Ingelheim, where he most recently served as Site Quality Head and Executive Director. His prior position at the company was Director, Quality Assurance. Previously, Barrera served in various positions at Genentech Inc. which include: Associate Director, Manufacturing Quality Assurance; Senior Manager, Commercial Inspection Operations; Senior Technical Manager, Distribution Quality; Manager, QA Operations; Change Control Senior Supervisor/Manager; and, QA Biochemical Operations. His earlier career includes positions at Chiron, Inc. and Bayer Corporation.
Barrera received his MBA from St. Mary’s College of California and BA in Integrative Biology and Environmental Science from University of California, Berkeley.
About Theravance Biopharma
The mission of Theravance Biopharma (NASDAQ: TBPH) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.
The company’s pipeline of internally discovered product candidates includes potential best-in- class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV® (telavancin), its first commercial product, is a once- daily dual-mechanism antibiotic approved in the U.S. and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for COPD. Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). The company’s earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, the company has an economic interest in future payments that may be made by GSK pursuant to its agreements with Theravance, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (or the "Closed Triple").
With a successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, Theravance Biopharma believes that it is well positioned to create value for shareholders and make a difference in the lives of patients.